Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 184 clinical trials
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted

  • 2 views
  • 22 Sep, 2021
  • 78 locations
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti

vascular endothelial growth factor
vitrectomy
bevacizumab
type 2 diabetes mellitus
visual loss
  • 5 views
  • 22 Jan, 2021
  • 1 location
Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine the

mitomycin
growth factor
solid tumor
neutrophil count
  • 0 views
  • 07 Nov, 2020
  • 1 location
Treat-and-extend Using Aflibercept for Type 3 Neovascularization

-used, effective anti-vascular endothelial growth factor treatment regimen for neovascular AMD, regardless of subtypes of AMD. The purpose of the present study is to investigate the 18-month treatment

  • 0 views
  • 04 Mar, 2021
  • 1 location
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP

vascular endothelial growth factor
vegf
blindness
antiangiogenic therapy
bevacizumab
  • 4 views
  • 07 Nov, 2020
  • 1 location
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more

  • 0 views
  • 02 May, 2021
  • 1 location
Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Telangiectasia (HHT) is a disorder that causes abnormal blood vessel formation. In HHT, there is a mutation in the TGF- pathway, which results in an increase of vascular endothelial growth factor (VEGF) levels

  • 0 views
  • 10 Jul, 2021
  • 1 location
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3

kinase inhibitor
serum pregnancy test
metastatic cancer
hysterectomy
measurable disease
  • 46 views
  • 22 Sep, 2021
  • 12 locations
Modulation of Tissue Sodium in Hemodialysis Patients

dialysis session. Tissue Na+ mobilization correlated with circulating vascular endothelial growth factor-C (VEGF-C). The investigators believe that excessive Na+ storage is a reversible condition and

  • 9 views
  • 27 Jan, 2021
  • 1 location
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Cholangiocarcinoma

development of cholangiocarcinoma (CCA) and chronic inflammation is a common underlying risk factor for CCA. Vascular endothelial growth factor (VEGF) signaling in CCA may lead to an immune suppression via

  • 0 views
  • 26 Aug, 2021
  • 2 locations